WHF IASC Roadmap on Chagas Disease.
| Autor: | Echeverría LE; Department of Cardiology, Cardiovascular Foundation of Colombia, Floridablanca, CO., Marcus R; LASOCHA, Washington DC, US.; Medstar Union Memorial Hospital, Baltimore, MD, US., Novick G; Swiss Medical Group, Buenos Aires, AR.; Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, US., Sosa-Estani S; Drugs for Neglected Diseases initiative-Latin America, Rio de Janeiro, BR., Ralston K; World Heart Federation, Geneva, CH., Zaidel EJ; Sanatorio Güemes, Buenos Aires, AR.; Pharmacology Department, School of Medicine, University of Buenos Aires, Buenos Aires, AR., Forsyth C; Drugs for Neglected Diseases initiative-Latin America, Rio de Janeiro, BR., RIbeiro ALP; Internal Medicine Department, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, BR.; Hospital das Clínicas, UFMG, Belo Horizonte, BR., Mendoza I; Central University of Venezuela, Caracas, VE., Falconi ML; Cardiology Division, Italian Hospital of Buenos Aires, Buenos Aires, AR.; University Institute of the Italian Hospital of Buenos Aires, Buenos Aires, AR., Mitelman J; Faculty of Medicine, University of Buenos Aires, Buenos Aires, AR.; School of Medicine, Barcélo University, Buenos Aires, AR., Morillo CA; Department of Cardiac Sciences, Cumming School of Medicine Division of Cardiology, Libin Cardiovascular Institute, University of Calgary, Calgary, CA.; Southeastern Alberta Region, Alberta Health Services, Foothills Medical Centre, CA., Pereiro AC; Mundo Sano Foundation, Buenos Aires, AR., Pinazo MJ; ISGlobal, Hospital Clínic, University of Barcelona, Barcelona, ES., Salvatella R; PAHO/WHO, Montevideo, UY., Martinez F; National University of Cordoba, Cordoba, AR.; DAMIC Institute/Rusculleda Foundation, Cordoba, AR., Perel P; World Heart Federation, Geneva, CH.; Centre for Global Chronic Conditions, London School of Hygiene and Tropical Medicine, London, GB., Liprandi ÁS; Sanatorio Güemes, Buenos Aires, AR.; Medical School of Cardiology, University of Buenos Aires, Buenos Aires, AR., Piñeiro DJ; Faculty of Medicine, University of Buenos Aires, Buenos Aires, AR., Molina GR; School of Medicine, CES University, Medellín, CO. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Global heart [Glob Heart] 2020 Mar 30; Vol. 15 (1), pp. 26. Date of Electronic Publication: 2020 Mar 30. |
| DOI: | 10.5334/gh.484 |
| Abstrakt: | Background: Chagas Disease is a neglected tropical disease caused by the protozoan Trypanosoma cruzi , with some of the most serious manifestations affecting the cardiovascular system. It is a chronic, stigmatizing condition, closely associated with poverty and affecting close to 6 million people globally. Although historically the disease was limited to endemic areas of Latin America recent years have seen an increasing global spread. In addition to the morbidity and mortality associated with the disease, the social and economic burdens on individuals and society are substantial. Often called the 'silent killer', Chagas disease is characterized by a long, asymptomatic phase in affected individuals. Approximately 30% then go on develop chronic Chagas cardiomyopathy and other serious cardiac complications such as stroke, rhythm disturbances and severe heart failure. Methods: In a collaboration of the World Hearth Federation (WHF) and the Inter-American Society of Cardiology (IASC) a writing group consisting of 20 diverse experts on Chagas disease (CD) was convened. The group provided up to date expert knowledge based on their area of expertise. An extensive review of the literature describing obstacles to diagnosis and treatment of CD along with proposed solutions was conducted. A survey was sent to all WHF Members and, using snowball sampling to widen the consultation, to a variety of health care professionals working in the CD global health community. The results were analyzed, open comments were reviewed and consolidated, and the findings were incorporated into this document, thus ensuring a consensus representation. Results: The WHF IASC Roadmap on Chagas Disease offers a comprehensive summary of current knowledge on prevention, diagnosis and management of the disease. In providing an analysis of 'roadblocks' in access to comprehensive care for Chagas disease patients, the document serves as a framework from which strategies for implementation such as national plans can be formulated. Several dimensions are considered in the analysis: healthcare system capabilities, governance, financing, community awareness and advocacy. Conclusion: The WHF IASC Roadmap proposes strategies and evidence-based solutions for healthcare professionals, health authorities and governments to help overcome the barriers to comprehensive care for Chagas disease patients. This roadmap describes an ideal patient care pathway, and explores the roadblocks along the way, offering potential solutions based on available research and examples in practice. It represents a call to action to decision-makers and health care professionals to step up efforts to eradicate Chagas disease. Competing Interests: MLF has received financial support for inscription to an international meeting from Philips/Agimed Argentina. RM previously worked in a consultancy role for Exeltis and Bayer. GM has received grants for global health research and projects from Novartis. LEE has received a research grant for work on Chagas cardiomyopathy from Roche. He is also a member of the steering committee of the PARACHUTE-HF trial. (Copyright: © 2020 The Author(s).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|